Background: Roughly 20-40% of individuals with idiopathic nephrotic syndrome will fail to respond to standard therapies and have a high risk of progression to end stage kidney disease (ESKD). In the last 50 years, no new therapies have been approved specifically for the treatment of these individuals with recalcitrant disease. Summary: Recent in vitro, translational, and clinical studies have identified novel targets and pathways that not only expand our understanding of the complex pathophysiology of proteinuric disease but also provide an opportunity to challenge the tradition of relying on histologic classification of nephrotic diseases to make treatment decisions. Key Messages: The traditional methods of directing the care of individuals with nephrotic syndrome by histological classification or deciding second line therapies on the basis of steroid-responsiveness may soon yield customizing therapies based on our expanding understanding of molecular targets. Important non-immunologic mechanisms of widely used immunosuppressive therapies may be just as important in palliating proteinuric disease as proposed immunologic functions.

Keywords:
Nephrotic syndrome, Immunosuppression, Novel therapies
1.
Sprague RG: Summary: cortisone and ACTH in clinical medicine. Proc Staff Meet Mayo Clin 1950;25:500-502.
2.
Sprague RG, Power MH, et al: Observations on the physiologic effects of cortisone and ACTH in man. Arch Intern Med (Chic) 1950;85:199-258.
3.
Barnett HL, et al: The effects of ACTH and cortisone on the nephrotic syndrome. AMA Am J Dis Child 1950;80:519-520.
4.
Gong R: Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis 2014;21:134-151.
5.
Berg AL, Arnadottir M: ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004;19:1305-1307.
6.
Hogan J, et al: Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 2013;8:2072-2081.
7.
Bomback AS, Radhakrishnan J: Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 2011;12:91-96.
8.
Ponticelli C, et al: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006;47:233-240.
9.
Rauen T, et al: Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009;71:637-642.
10.
Hladunewich MA, et al: A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant 2014;29:1570-1577.
11.
Zietse R, et al: Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci (Lond) 1992;82:641-650.
12.
Meyrier A: Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transplant 1992;(7 suppl 1):80-84.
13.
Faul C, et al: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-938.
14.
Kemper MJ, Wolf G, Muller-Wiefel DE: Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001;344:386-387.
15.
Dantal J, et al: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
16.
Savin VJ, et al: Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008;151:288-292.
17.
Savin VJ, et al: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878-883.
18.
Sharma M, et al: Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002;73:366-372.
19.
Trachtman H, et al: Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 2011;12:8.
20.
Stambe C, et al: Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 2003;14:338-351.
21.
Sheryanna A, et al: Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 2007;18:1167-1179.
22.
Koshikawa M, et al: Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005;16:2690-2701.
23.
Daehn I, et al: Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014;124:1608-1621.
24.
Buelli S, et al: Beta-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 2014;25:523-533.
25.
Ravani P, et al: Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013;84:1025-1033.
26.
Ruggenenti P, et al: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014;25:850-863.
27.
Bruchfeld A, et al: Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant 2014;29:851-856.
28.
Iijima K, et al: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384:1273-1281.
29.
Kamei K, et al: Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 2014;29:1181-1187.
30.
Sinha A, et al: Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 2014;pii: gfu267, Epub ahead of print.
31.
Perosa F, et al: Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070-1077.
32.
Reiser J, et al: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113:1390-1397.
33.
Yu CC, et al: Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369:2416-2423.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.